Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus
2019-001854-24Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Jul 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in Kidney allograft status (RTx) (2 arms), sponsored by Erasmus MC. Primary endpoint: Long-term outcomes (tacrolimus vs tacrolimus + mycophenolate mofetil). Started Jul 2019; status: active.
02
Drugs
tacrolimus
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2019-001854-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001854-24.